Navigation Links
Astute Nanotechnology celebrates first year of success
Date:4/30/2008

University of Queensland-based Astute Nanotechnology will celebrate the achievements of its first year in business with a special presentation and cocktail reception tomorrow Tuesday, April 29.

Astute Nanotechnology creates opportunities for industry partners to access the expertise and resources of scientists at the ARC Centre of Excellence for Functional Nanomaterials (ARC CFN).

Located within the Australian Institute for Bioengineering and Nanotechnology (AIBN) at UQ, Astute Nanotechnology is a trading business of UniQuest Pty Limited, one of Australia's leading technology transfer companies for public sector research. A highlight of Astute Nanotechnology's first anniversary celebration will be an address by world-renowned academic and founding director of the ARC CFN, Professor Max Lu. His presentation will promote the clean-tech' innovations being developed by his team of scientists at The University of Queensland, the University of NSW, the Australian National University and the University of Western Sydney.

Dr Richard Taylor, a director of the Australian Nanotechnology Alliance (ANA), will offer the closing remarks. The event is supported by the ARC CFN, ANA, AIBN and UniQuest.

UniQuest's Managing Director, Mr David Henderson, said Astute Nanotechnology had achieved an impressive record in its short life, including 18 scientific disclosures and nine patent applications.

Astute Nanotechnology is connecting industry partners with university researchers for what is now being called the dot.watt' boom. The clean-tech industry is estimated to be worth more than $150 billion, with global investment in clean energy alone experiencing 60% growth in the past year or so. All kinds of industries are keen to invest in the development of alternative energy sources and smarter water treatment systems, Mr Henderson said.

As the current debate on climate change has shown, the need for research on how b
'/>"/>

Contact: Leanne Wyvill
communications@uq.edu.au
61-733-654-037
Research Australia
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Hill-Rom Selects NanoHorizons to Provide Antimicrobial Protection for Hill-Rom Products Using Nanotechnology
2. Breakthroughs in nanotechnology on edge of knowledge frontier
3. Federal toxics disclosure law could help inform public of nanotechnology risks
4. Cleaner water through nanotechnology
5. Nanotechnologys future depends on who the public trusts
6. UCLA-industry partnership to develop, commercialize new nanotechnology
7. Food and Drug Law Institute, Project on Emerging Nanotechnologies Co-Sponsor Major Conference on Nanotechnology Law, Regulation and Policy
8. Nanotechnology: not just for geeks
9. Prime Clinical Systems Celebrates Silver Anniversary
10. Anthem Blue Cross and Blue Shield Celebrates Local Moms-to-Be at Community Baby Shower
11. Entertainment Industry Foundation Revlon Run/Walk for Women Celebrates 11 Years in New York City on Saturday, May 3
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 1KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 2KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 4KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 5KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 6Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 1Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 2Alzheimers Soars Global Focus Needed 3A Study 57748 1Alzheimers Soars Global Focus Needed 3A Study 57748 2Alzheimers Soars Global Focus Needed 3A Study 57748 3
Other Medicine Technology:Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10